NCT07182279View on ClinicalTrials.gov

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

November 14, 2026

Study Completion Date

November 14, 2026

Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
DRUG

Brachytherapy

All patients will receive a single fraction of HDR-B (15Gy) 4-8 weeks prior to RALP. Patients with high genomic risk or node positivity will receive short course adjuvant AAB.

Trial Locations (1)

77030

RECRUITING

Houston Methodist, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER

NCT07182279 - Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter